Skip to content

BCBS Nebraska

Does BCBS Nebraska cover Ozempic?

Yes. BCBS Nebraska covers Ozempic for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered (preferred drug). See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Ozempic for Type 2 Diabetes (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

Preferred GLP-1 - Prior Use within 90 Days

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C ≥ 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Patient treated with a preferred agent within the past 90 days (samples not approvable)
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Preferred GLP-1 - New Start

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C ≥ 6.5%)
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Ozempic is a preferred GLP-1 agent
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C ≥ 6.5%
  • Documentation of patient age within FDA labeling OR clinical support for off-label age use
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent
  • If prior use pathway: documentation of prior preferred agent use within past 90 days (samples not acceptable)

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month
  • 1.5mg tablet, 4mg tablet, 9mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent
  • Use for non-FDA approved indications (considered investigational unless excluded by contract)

Policy note: Ozempic (injection) and Rybelsus (tablet/oral semaglutide) are both listed as preferred agents. Policy includes Ozempic tablets (1.5mg, 4mg, 9mg) as of 05-04-2026 revision at parity with Rybelsus tablets. Ozempic is a preferred agent so no step therapy through other GLP-1s is required. Non-preferred agents require trial/failure of TWO preferred agents (90 days each). Metformin step therapy was removed as of 04-01-2026.

Policy effective November 5, 2025 · verified June 2, 2026 · source: Policy 212 · View policy document (PDF)

Open on its own page →

Full requirements: Ozempic for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in T2DM with Established CVD

All of:

  • Patient has diagnosis of type 2 diabetes mellitus
  • Diagnosis confirmed by lab (A1C ≥ 6.5%)
  • Established cardiovascular disease
  • Age within FDA labeling for requested indication OR support provided for requested age
  • Will NOT be used in combination with a DPP-4 containing agent
  • Will NOT be used in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to the requested agent

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Lab result confirming A1C ≥ 6.5%
  • Documentation of established cardiovascular disease
  • Attestation that patient will not use in combination with a DPP-4 containing agent
  • Attestation that patient will not use in combination with another GLP-1 receptor agonist
  • Attestation of no FDA labeled contraindications to the requested agent

Quantity limits

  • 0.25mg dose, 0.5mg dose — 1 pen (2mg/1.5mL) per month
  • 1mg dose — 1 pen (4mg/3mL) per month
  • 2mg dose — 1 pen (8mg/3mL) per month

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must have had clinical benefit with the requested agent.

Not covered when

  • Combination use with DPP-4 containing agents
  • Combination use with another GLP-1 receptor agonist
  • FDA labeled contraindications to the requested agent

Policy note: Policy states Ozempic is FDA approved to reduce risk of major adverse cardiovascular events in adults with T2DM and established CVD. The policy criteria do not separate CV risk reduction from diabetes criteria in explicit steps — the same general pathway applies with T2DM diagnosis and established CVD as the indication. Specific qualifying CV events (MI, stroke, PAD) are not enumerated in this policy. Since Ozempic is preferred, no GLP-1 step therapy is required.

Policy effective November 5, 2025 · verified June 2, 2026 · source: Policy 212 · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Nebraska cover Ozempic?
Yes. BCBS Nebraska covers Ozempic for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Ozempic approval last with BCBS Nebraska?
Type 2 Diabetes — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Nebraska require to renew Ozempic?
Type 2 Diabetes — Applies to Employer and ACA Marketplace plans. Patient must have had clinical benefit with the requested agent. No re-verification of T2DM diagnosis, A1C threshold, or step therapy at renewal. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Patient must have had clinical benefit with the requested agent.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Nebraska: Mounjaro, Wegovy, Zepbound

Ozempic under other plans: Molina Healthcare, Nebraska Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Kansas, BCBS Louisiana, BCBS Massachusetts

All insurance plans · All medications

Summary of BCBS Nebraska's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.